Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VCs Piling Into Oncology, Chasing Pharma Deals

This article was originally published in Start Up

Executive Summary

Oncology continues to dominate the therapeutic focus of VC investors. Here we take a look at the 181 private biotechnology companies funded so far this year to determine which therapeutic areas are hot.

You may also be interested in...



Therapeutic Area Partnerships: Faster, Earlier and Make Mine Cash

The rising dealmaking value of proof of concept (POC) was the key theme at Windhover's Therapeutic Area Partnerships meeting, (Oct. 24-26, 2007). In 2002 and 2003 companies paid roughly three times the value for Phase III products that they paid for Phase II. Now, candidates at Phase II (a proxy for POC) go for about the same price as Phase III drugs. What’s going on here and what role will Big Pharma and mid-size companies find themselves playing if the trend continues?

Therapeutic Area Partnerships: Faster, Earlier and Make Mine Cash

The rising dealmaking value of proof of concept (POC) was the key theme at Windhover's Therapeutic Area Partnerships meeting, (Oct. 24-26, 2007). In 2002 and 2003 companies paid roughly three times the value for Phase III products that they paid for Phase II. Now, candidates at Phase II (a proxy for POC) go for about the same price as Phase III drugs. What’s going on here and what role will Big Pharma and mid-size companies find themselves playing if the trend continues?

Movetis Takes GI from J&J

VCs love a part-baked start-up, and one of the best places to find them is within Big Pharma. So it was that Belgium-based Movetis NV raised a record €49 million ($63.4 million) A round in January with a bunch of gastrointestinal-focused assets from Johnson & Johnson.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091345

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel